CTAG1B and ovarian carcinoma: A number of ovarian cancer trials have been conducted in patients using vaccinations with ESO 157-170, a short peptide of the CTA NY-ESO-1 [271], and heterologous prime-boost vaccinations [6], i.e., multiple vaccinations with different delivery vectors encoding the same recombinant antigen [272].